Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)

Forming a Comprehensive Treatment Plan for the Treatment of Hepatitis B Virus Related Hepatocellular Carcinoma With the Core Principles of Fuzheng Jiedu Huayu

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05152498

Enrollment

142

Registered

2021-12-09

Start date

2021-01-01

Completion date

2023-12-31

Last updated

2021-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine Fu Zheng Jie Du Hua Yu Principle.

Interventions

DRUGFu Zheng Jie Du Hua Yu therapy

Fu Zheng Jie Du Hua Yu is a Chinese herbal compound

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Meet the criteria of hepatocellular carcinoma * Ages Eligible for Study: ≤75 years old; * Informed consent from the patient.

Exclusion criteria

* Serious problem of heart, lung, or kidney with severe dysfunction; * Pregnant or child breast feeding women; * Mental or cognitive disorders; * Participating in other drug trials; * Who are allergic to the study drug

Design outcomes

Primary

Measure	Time frame
Time to Progression	1 year

Secondary

Measure	Time frame
overall survival	1 year
progression-free survival	1 year
complete response	1 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026